Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited reports significant advancements in its FAK inhibitor program for treating cancer, with the Phase 2a ACCENT trial for pancreatic cancer underway and new trial sites operational in South Korea. The company has obtained FDA clearance to commence a trial in the USA and announced a funding offer to support ongoing clinical developments. At the end of the March 2024 quarter, Amplia had a cash position of $3.4 million, with an expected increase in research and development expenditures as the ACCENT trial progresses.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
